substance withdrawal syndrome
substance withdrawal syndrome
Explore linked clinical trials. Standard reference: MONDO:00055679 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Preventox - a Digital Intervention for Patients With Intoxications in Intensive Care | Alcohol-Induced Disorders, Nervous System, Chemically-Induced Disorders, alcohol withdrawal delirium, alcohol-induced disorders, alcohol-related disorders, nervous system disorder, poisoning, psychiatric disorder, substance withdrawal syndrome, substance-related disorder, toxic encephalopathy | Not yet recruiting | Not applicable | 2026-09-23 | NCT07819500 | |
| Dexmedetomidine for Invasive Ventilation In the NEOnate | Chemically-Induced Disorders, Neurobehavioral Manifestations, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, agnosia, neonatal respiratory failure, nervous system disorder, perceptual disorders, psychiatric disorder, substance withdrawal syndrome, substance-related disorder | Not yet recruiting | Phase 2 / Phase 3 | 2026-08-26 | NCT07493785 | |
| Neurostimulation to Improve NOWS Outcomes | Chemically-Induced Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, neonatal abstinence syndrome, psychiatric disorder, substance withdrawal syndrome, substance-related disorder | Active, not recruiting | Not applicable | 2026-06-02 | NCT05129020 | |
| Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal | Chemically-Induced Disorders, Chronic Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Withdrawal Symptoms, psychiatric disorder, substance withdrawal syndrome, substance-related disorder | Recruiting | Phase 2 | 2026-05-01 | NCT04939623 | |
| Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3 | Chemically-Induced Disorders, Narcotic-Related Disorders, Opioid Use Disorder, Withdrawal Symptoms, opiate dependence, psychiatric disorder, substance withdrawal syndrome, substance-related disorder | Recruiting | Phase 3 | 2026-03-27 | NCT05834478 | |
| Validation of the French Version of the Prediction of the Alcohol Withdrawal Severity Scale (PAWSS) | Alcohol Use Disorder, Chemically-Induced Disorders, alcohol withdrawal, alcohol-related disorders, psychiatric disorder, substance dependence, substance withdrawal syndrome, substance-related disorder | Recruiting | Not stated | 2025-02-25 | NCT06675539 | |
| Kratom Use Disorder Management Using Clonidine and/or Buprenorphine | Chemically-Induced Disorders, psychiatric disorder, substance withdrawal syndrome, substance-related disorder | Recruiting | Not stated | 2025-01-27 | NCT05883358 | |
| Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia | Chemically-Induced Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm, psychiatric disorder, substance withdrawal syndrome, substance-related disorder | Active, not recruiting | Phase 2 | 2024-11-26 | NCT04147533 | |
| Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease | Chemically-Induced Disorders, Disease Attributes, Graves disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hyperthyroidism, immune system disorder, psychiatric disorder, substance withdrawal syndrome, substance-related disorder, thyroid gland disorder | Recruiting | Phase 4 | 2023-12-11 | NCT05461820 |